Pharmaceuticals & Biotechnology
Science sets the timeline. Finance sets the runway.
Emerging biotech and pharma companies manage long development programs with finite capital.
How capital moves through drug development
Long development timelines
Drugs take many years and multiple trial phases to reach market.
Read more: Long development timelines
Drug development progresses from discovery through preclinical work and clinical trial phases before regulatory submission. Each phase is more expensive than the last, and many candidates fail. Timelines often span a decade or more. Spending is driven by trial enrollment, manufacturing of clinical supply, and regulatory activities. Financial planning must reflect phase-by-phase costs, probability of success, and realistic timing. Probability-weighted models help boards compare programs consistently.
Partnerships and licensing
Collaborations provide capital and expertise in exchange for rights.
Read more: Partnerships and licensing
Biotech companies often partner with larger pharmaceutical companies through licensing or collaboration agreements. These provide upfront payments, milestone payments, research funding, and royalties, in exchange for rights to products or territories. Partnership terms affect revenue recognition, cash timing, and long-term value. Evaluating partnership offers requires modeling the economics of retaining versus sharing rights. Partnership terms also influence future financing options and the attractiveness of the company to acquirers.
Equity-funded runway
Most development is funded by equity raised in stages.
Read more: Equity-funded runway
Development-stage companies rely primarily on venture capital and public equity, supplemented by partnerships, grants, and sometimes debt. Capital is raised around data readouts and other value inflection points. Market conditions strongly affect valuation and availability. Runway planning must include margin for trial delays and the possibility that financing markets are unfavorable when capital is needed.
Commercialization and market access
Approval begins a new phase of investment.
Read more: Commercialization and market access
Commercial launch requires manufacturing scale-up, sales and medical affairs teams, distribution, and market access efforts with payers. Pricing and reimbursement determine revenue potential, and rebates and discounts create significant gross-to-net adjustments. Launch investment can be substantial before revenue builds. Financial planning must address these costs and the timing of payer coverage decisions.
Where pharmaceutical and biotech companies feel pressure
Trial cost and timing
Enrollment delays and protocol changes raise cost.
Read more: Trial cost and timing
Clinical trials frequently take longer or cost more than planned because of enrollment challenges or protocol amendments. These changes extend runway needs. Tracking trial spending against budget and modeling scenarios helps leadership anticipate financing needs and communicate clearly with boards.
Financing market volatility
Capital availability varies widely over time.
Read more: Financing market volatility
Biotech financing markets fluctuate, and companies may face difficult conditions just as they need capital. Raising on poor terms can cause significant dilution. Extending runway through prioritization and planning financings well ahead of need reduces this risk.
Portfolio prioritization
Limited capital must be allocated across programs.
Read more: Portfolio prioritization
Companies with multiple programs must decide which to advance, partner, or pause. These decisions depend on scientific data, competitive landscape, and financial capacity. Financial modeling of each program's cost and value supports more disciplined portfolio decisions.
Partnership evaluation
Deal terms affect long-term value.
Read more: Partnership evaluation
Upfront and milestone payments can provide valuable capital, but sharing rights reduces future economics. Comparing partnership offers with alternative financing requires careful modeling of cash, dilution, and retained value. Legal terms remain with counsel. Each program deserves careful analysis. Cash timing deserves close attention too.
Gross-to-net and launch planning
Rebates and discounts reduce net revenue.
Read more: Gross-to-net and launch planning
Commercial products face rebates, discounts, and fees that can significantly reduce net revenue. Underestimating gross-to-net adjustments leads to overly optimistic forecasts. Launch plans should reflect realistic net pricing and coverage timelines. Assumptions should be reviewed with commercial leaders, and updated as payer negotiations progress through launch.
Finance function maturity
Investors and partners require robust reporting.
Read more: Finance function maturity
Development-stage companies often have small finance teams. Clinical accruals, partnership accounting, and equity reporting become complex quickly. Strengthening processes before major financings, partnerships, or public listing reduces risk and diligence friction. Auditors and partners will expect consistent, well-documented accounting policies.
Advisory for development-stage and commercial life sciences companies
Finance & Accounting Advisory
Fractional CFO leadership, clinical accruals, and investor reporting.
Read more: Finance & Accounting Advisory
Perrin & Co. provides fractional or interim CFO leadership, clinical trial accrual processes, budgeting, board and investor reporting, and close improvements. Work covers finance and operations only and does not include clinical, regulatory, or scientific advisory services.
Business Advisory
Runway, portfolio, and partnership modeling.
Read more: Business Advisory
Financial decision support models runway, program-level costs and value, and partnership alternatives, helping boards prioritize programs and evaluate offers. Launch economics, including gross-to-net assumptions, are tested against realistic scenarios rather than optimistic forecasts. Each analysis is reviewed with the board and updated as data readouts arrive.
Capital Structure & Financing
Non-dilutive and debt alternatives analysis as borrower.
Read more: Capital Structure & Financing
Perrin & Co. analyzes venture debt, royalty-based financing, and grant funding against equity alternatives, and supports management in lender discussions as borrower. The firm does not raise equity, place securities, or act as placement agent or investment bank. Terms vary by facility.
Technology Solutions
Systems for accruals, budgeting, and reporting.
Read more: Technology Solutions
Perrin & Co.'s Technology Solutions capability can help implement budgeting, accrual tracking, and reporting systems that support growing finance teams. Work concerns financial systems only and excludes clinical trial management or regulatory systems. Better systems also reduce audit preparation time.
Where to start
Scope qualification. Perrin & Co. provides financial and operational advisory only. We do not provide clinical, medical coding, reimbursement compliance, regulatory, licensure, or legal advice, and this page does not represent specialized healthcare regulatory credentials. Those matters remain with qualified healthcare counsel and specialists.
More in Healthcare & Life Sciences
Discuss your pharmaceuticals & biotechnology priorities
A confidential conversation with Perrin & Co. — no obligation, and a candid view of whether we can help.